Navigation Links
Quigley Announces Successful Poultry Study of Chickens With Infectious Bronchitis; Plans to Approach the Poultry Industry for Potential Commercialization
Date:5/14/2008

DOYLESTOWN, Pa., May 14 /PRNewswire-FirstCall/ -- The Quigley Corporation (Nasdaq: QGLY) announced positive results from a study conducted by its wholly owned subsidiary, Quigley Pharma Inc., which was conducted in chickens to evaluate the anti-viral activity of its compound QR448(a). The compound was administered to chicks that had been infected with Infectious Bronchitis Virus (IBV). The data from the study indicated that QR448(a) is efficacious against an IBV challenge in two week old specific pathogen free (SPF) chicks, confirming previous results indicating that treatment with QR448(a) before or after viral exposure has the potential to lessen or prevent disease.

Preventing and treating infectious bronchitis caused by IBV is a worldwide concern of the poultry industry which calculates its loses due to this disease in lowered weight gains and feed efficiency in broilers, lowered production and quality of eggs in layers and breeders, mortality, clean-up costs and disruption to operations.

The Company initiated its investigations into the effectiveness of this compound based on feedback from poultry industry leaders who expressed an increasing need for additional products to combat Infectious Bronchitis (IBV).

Dr Richard Rosenbloom, Executive Vice President and Chief Operating Officer of Quigley Pharma stated: "With the increased emphasis by the animal health community on prevention as well as treatment of disease, the results from our experiments in chickens have demonstrated that our QR448(a) compound can prevent as well as treat 2 week old SPF chicks from infection when challenged with IBV in a dose response experimental design. We believe this innovative, non-vaccine, broad spectrum antiviral has the potential to offer the poultry industry a natural base solution to this growing problem."

With the completion of this latest study and the current dossier of data the company plans to solicit the poultry industry for additional guidance and potential interest and opportunities for developing this compound jointly toward commercialization.

About the study:

This study was conducted by Dr. Mark Jackwood Professor, Department of Population Health, College of Veterinary Medicine, University of Georgia who concluded that based on the results:

-- A 1:20 dilution of QR448(a) given to two week old chickens by aerosol

treatment at a dose of 1ml per bird 2 hours before challenge was

effective in significantly lowering the amount of challenge virus in

the trachea to undetectable levels (less than or equal to 100 EID [for

50%], p less than or equal to 0.2).

-- Aerosol treatment of QR448(a) 2 hours after challenge was effective at

lowering the amount of virus in the trachea to approximately 1 X 10 (to

the 2.5 power) EID (for 50%) (p less than or equal to 0.2), which is

significant, as disease is typically not observed when less than 1 X

10 (to the 3 power) EID (for 50%) is used for challenge.

-- Effective dosing was established between high and low concentrations of

QR448(a). Higher concentrations may have created an environment in the

upper-respiratory tract allowing virus infection to occur. In

addition, the lowest concentrations of QR448(a) appear to be

insufficient for preventing virus infection. The optimum dose was

established in this trial to be 1:20 dilution for success.

Dr. Jackwood stated: "The reduction of clinical signs and detection of fewer virus particles in chickens challenged with an extremely infectious and virulent strain of IBV was quite remarkable. There are many different types of IBV but generally one type of IBV vaccine only protects against the same virus type. The ability to mass deliver this all-natural compound ought to mesh well with a control program for IBV regardless of the type of the virus."

A chronological summary of the data from studies conducted to date on QR448(a):

-- The formulation was initially identified as QR441(a) and for its

anti-viral activity against Highly Pathogenic Avian Influenza H5N1.

-- In-vitro anti-viral activity was shown against IBV at maximum effective

non-toxic concentrations of QR448(a).

-- In embryonating eggs, non-toxic concentrations were shown to cause

100fold reductions in IBV titer with no noticeable adverse effects on

embryo developing chicks.

-- The best route of administration of QR448(a) to challenged 2 week old

SPF chicks was by aerosol spray as opposed to direct intranasal or

addition to drinking water.

-- Aerosol spray treatment of 2 week old SPF chickens with QR448(a) 6 or 2

hours before or 2 hours after challenge with IBV abrogates the course

of the disease by lowering the presence of virus in the trachea to

undetectable levels and reducing the severity of lesions in the

trachea.

-- A clear and safe dose response has been determined that provides a

significant log reduction in viral titer in the trachea of 2 week old

SPF chickens treated with QR448(a) 2 hours before or 2 hours after

challenge with IBV.

The Quigley Corporation makes no representation that the U.S. Food and Drug Administration or any other regulatory agency will issue an investigational new animal drug number or allow this compound to be marketed for IBV. Furthermore, no claim is made that the potential medicine discussed here is safe, effective, or approved by the Food and Drug Administration.

About The Quigley Corporation

The Quigley Corporation (Nasdaq: QGLY, http://www.Quigleyco.com) is a diversified natural health medical science company. Its Cold Remedy segment is a leading marketer and manufacturer of the COLD-EEZE(R) family of lozenges, gums and sugar free tablets clinically proven to cut the common cold nearly in half. COLD-EEZE customers include leading national wholesalers and distributors, as well as independent and chain food, drug and mass merchandise stores and pharmacies. The Quigley Corporation has wholly owned subsidiaries; Quigley Manufacturing Inc. consists of two FDA approved facilities to manufacture COLD- EEZE(R) lozenges as well as fulfill other contract manufacturing opportunities and Quigley Pharma Inc. (http://www.QuigleyPharma.com) conducts research in order to develop and commercialize a pipeline of patented botanical and naturally derived potential prescription drugs.

Forward-Looking Statements

Certain statements in this press release are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 and involve known and unknown risk, uncertainties and other factors that may cause the Company's actual performance or achievements to be materially different from the results, performance or achievements expressed or implied by the forward-looking statement. Factors that impact such forward-looking statements include, among others, changes in worldwide general economic conditions, changes in interest rates, government regulations, and worldwide competition.

CONTACT: Media Investor Relations

Karen Pineman Carl Hymans

G.S. Schwartz & Co. G.S. Schwartz & Co.

212.725.4500 212.725.4500

kpineman@schwartz.com carlh@schwartz.com


'/>"/>
SOURCE The Quigley Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. The Quigley Corporation Reports Third Quarter Results, Increases Investment in Pharmaceutical R&D for Diabetic Neuropathy
2. Kosan Announces Data Presentations at ASCO 2008 Annual Meeting
3. XTENT Announces Positive Six-Month CUSTOM III Trial Data Presented at EuroPCR Meeting
4. NicOx Announces Initiation of First Phase 1 Study of Investigational Nitric Oxide-Donating Agent in Hypertensive Patients by Merck & Co., Inc.
5. Alseres Pharmaceuticals Announces 12 Month Interim Results from the Phase I/IIa Cethrin(R) Clinical Trial in Acute Spinal Cord Injury
6. Medarex Announces Initiation of Phase 2 Clinical Trials for the Treatment of Ulcerative Colitis and Rheumatoid Arthritis
7. CryoLife Announces First Implant of Combination Aortic-Mitral Allograft Heart Valve at the Cleveland Clinic
8. Nventa Announces Additional Positive Immunological Data From HspE7 Phase 1 Cervical Dysplasia Trial
9. Ardea Biosciences Appoints John W. Beck Chief Financial Officer, Announces Clinical Development Progress and Reports First Quarter 2008 Financial Results
10. Cytopia Announces Novel Anti-Cancer Drug Development Collaboration
11. Vion Pharmaceuticals Announces Initiation of Clinical Trial of Cloretazine(R) (VNP40101M) in Combination with Cytarabine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016  In a startling report released today, ... their residents by lacking a comprehensive, proven plan to eliminate prescription ... definitive ranking of how states are tackling the worst drug crisis ... four states – Kentucky , New ... Vermont . Of the 28 failing states, three – ...
(Date:6/23/2016)... 2016 Research and Markets has announced ... report to their offering. ... a favourable commercial environment for MedImmune to enter. The US ... will serve to drive considerable growth for effective anti-influenza medications. ... cap sales considerably, but development is still in its infancy. ...
(Date:6/23/2016)... 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), a new affiliate with operations headquartered ... Latin America . ... ... ... ...
Breaking Medicine Technology:
(Date:6/27/2016)... ... June 27, 2016 , ... ... to revolutionize the emergency ambulance transport experience for the millions of people who ... Uber has disrupted the taxi industry through the use of technology. Now, SmartEMS ...
(Date:6/26/2016)... ... June 26, 2016 , ... Pixel Film Studios Released ProSlice Levels, a ... can give their videos a whole new perspective by using the title layers ... Film Studios. , ProSlice Levels contains over 30 Different presets to choose from. ...
(Date:6/25/2016)... ... 2016 , ... Experts from the American Institutes for Research ... June 26-28, 2016, at the Hynes Convention Center in Boston. , AIR experts ... planning, healthcare costs and patient and family engagement. , AIR researchers will be ...
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency ... named Dr. Sesan Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. ... Director of our new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of ... of the latter, setting the bar too high can result in disappointment, perhaps even ... progress toward their goal. , Research from PsychTests.com reveals that behind ...
Breaking Medicine News(10 mins):